Moderna and Merck mRNA Vaccine Reduces Melanoma Recurrence and Death by 42%
Moderna and Merck have released promising trial results showing their personalized mRNA cancer vaccine significantly reduces the risk of death or recurrence in melanoma patients by 42 percent. This milestone highlights the growing potential of mRNA technology beyond infectious diseases, offering a new frontier in targeted, personalized oncology treatments.
Source: Ars Technica